TY - JOUR
T1 - Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1
T2 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
AU - Sulzgruber, Patrick
AU - Wassmann, Sven
AU - Semb, Anne Grete
AU - Doehner, Wolfram
AU - Widimsky, Petr
AU - Gremmel, Thomas
AU - Kaski, Juan Carlos
AU - Savarese, Gianluigi
AU - Rosano, Giuseppe M C
AU - Borghi, Claudio
AU - Kjeldsen, Keld
AU - Torp-Pedersen, Christian
AU - Schmidt, Thomas Andersen
AU - Lewis, Basil S
AU - Drexel, Heinz
AU - Tamargo, Juan
AU - Atar, Dan
AU - Agewall, Stefan
AU - Niessner, Alexander
N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: [email protected].
PY - 2019
Y1 - 2019
N2 - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.
AB - Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.
U2 - 10.1093/ehjcvp/pvz016
DO - 10.1093/ehjcvp/pvz016
M3 - Journal article
C2 - 31119266
VL - 5
SP - 171
EP - 180
JO - European Heart Journal - Cardiovascular Pharmacotherapy
JF - European Heart Journal - Cardiovascular Pharmacotherapy
SN - 2055-6837
IS - 3
ER -